ScholarLens Back to search
2021•Medycyna FaktówOpen access

The use of tadalafil and tamsulosin in benign prostatic hyperplasia

Kajetan Juszczak, Tomasz Drewa

Open full text 0 citations

Abstract

Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are common in aging men. There is a close relationship between LUTS complaints and erectile dysfunction. Alpha-blockers are usually considered the I-line treatment of BPH-related LUTS. Phosphodiesterase 5 inhibitors are the gold standard in the treatment of erectile dysfunction, and can also be used in patients with BPH-related LUTS with or without coexisting erectile dysfunction. This article presents the current state of knowledge regarding the use of an α-blocker (tamsulosin) and a phosphodiesterase- 5 inhibitor (tadalafil) in the treatment of benign prostatic hyperplasia.

About this research paper

What this paper is about

Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are common in aging men. There is a close relationship between LUTS complaints and erectile dysfunction. Alpha-blockers are usually considered the I-line treatment of BPH-related LUTS. Phosphodiesterase 5 inhibitors are the gold standard in the treatment of erectile dysfunction, and can also be used in patients with BPH-related LUTS with or without coexisting erectile dysfunction. This article presents the current state of knowledge regarding the use of an α-blocker (tamsulosin) and a phosphodiesterase- 5 inhibitor (tadalafil) in the treatment of benign prostatic hyperplasia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are common in aging men. There is a close relationship between LUTS complaints and erectile dysfunction. Alpha-blockers are usually considered the I-line treatment of BPH-related LUTS. Phosphodiesterase 5 inhibitors are the gold standard in the treatment of erectile dysfunction, and can also be used in patients with BPH-related LUTS with or without coexisting erectile dysfunction. This article presents the current state of knowledge regarding the use of an α-blocker (tamsulosin) and a phosphodiesterase- 5 inhibitor (tadalafil) in the treatment of benign prostatic hyperplasia.

Key concepts: Tadalafil, Tamsulosin, Lower urinary tract symptoms, Erectile dysfunction, Medicine, Urology, cGMP-specific phosphodiesterase type 5, Hyperplasia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The use of tadalafil and tamsulosin in benign prostatic hyperplasia — Research Paper | ScholarLens